(a) A pharmacist planning to engage in collaborative practice shall have on file at the pharmacist's place of practice a written, signed collaborative practice agreement approved by the Board. This collaborative practice agreement allows the pharmacist, acting within the pharmacist's collaborative scope of practice, to conduct MTM approved by a prescribing practitioner acting within the scope of the practitioner's current practice.
(b) The collaborative practice agreement shall include: - (i) The names of the prescribing practitioner and the pharmacist who are parties to the collaborative practice agreement;
- (ii) The specific types of MTM decisions that the pharmacist is allowed to make, which shall include:
- (A) The types of diseases, drugs or drug categories involved, and the extent of MTM allowed in each case;
- (B) The methods, procedures, decision criteria and plan the pharmacist is to follow when conducting MTM; and
- (C) The procedures the pharmacist is to follow in the course of conducting MTM, including documentation of decisions and a plan or appropriate mechanism for communication and reporting to the prescribing practitioner concerning specific decisions. Documentation of decisions shall occur in the prescribing practitioner patient medical record. If the medical record is not available at the practice site, a copy of the documentation of decisions will be sent to the prescribing practitioner.
- (iii) A method for the prescribing practitioner to monitor compliance with the collaborative practice agreement and clinical outcomes when MTM by the pharmacist has occurred and to intercede when necessary;
- (iv) A provision that allows the prescribing practitioner to override the collaborative practice agreement whenever deemed necessary or appropriate;
- (v) A provision allowing the practitioner, pharmacist and patient or patient's agent, parent or guardian to cancel the collaborative practice agreement at any time by written notice to all parties. The pharmacist shall retain the original notice of cancellation for two (2) years; and
- (vi) The signatures of the pharmacist and prescribing practitioner who are entering into the collaborative practice agreement and the dates when signed.
(c) MTM shall occur only for a particular patient pursuant to a specific written order from the prescribing practitioner. The written order shall conform to the format established by the Board and shall include the following as a minimum: - (i) Patient's name, gender, date of birth, height and weight;
- (iv) All current medication(s), including current dosages (including any laboratory test);
- (v) Method of communicating information between pharmacist and practitioner;
- (vi) Frequency of practitioner follow-up;
- (vii) Date the order will be renewed (specific order must be renewed annually); and
- (viii) Signatures of the practitioner, pharmacist and patient or the patient's agent, parent or guardian, and date signed.
(d) A pharmacist providing MTM for a patient shall obtain written consent from the patient or the patient's agent, parent or guardian prior to providing this service. MTM shall not be implemented for a particular patient, if the patient or patient's agent, parent or guardian refuses to give written consent after being informed of the responsibility for payment.
(e) At a minimum, the written collaborative practice agreement shall be reviewed and renewed annually. If necessary, the collaborative practice agreement may be revised. The Board must approve all revisions, once signed by the pharmacist and the prescribing practitioner, prior to implementation. The Board shall review and approve all collaborative practice agreements, including revisions, prior to implementation. This shall be accomplished as follows: - (i) The Board shall appoint a Collaborative Practice Advisory Committee. The Committee shall be composed of five (5) members. Composition shall be two (2) pharmacists currently licensed by the Board and in active practice in Wyoming, one of whom is a current member of the Board; two (2) physicians currently licensed by the Wyoming State Board of Medicine and in active practice in Wyoming one of whom is a current member of the Board of Medicine; and the Board of Pharmacy Executive Director;
- (ii) A pharmacist who has developed a collaborative practice agreement shall forward five (5) copies of the signed collaborative practice agreement to the Board. The Executive Director shall convene the Committee to review pending collaborative practice agreements. The Committee shall have authority to recommend approval or rejection of the collaborative practice agreement;
- (iii) The recommendation of the Committee shall be reported to the Board at their next regularly scheduled meeting or as needed. The Board's decision will be delivered to the pharmacist and prescribing practitioner within ten (10) days of the Board's decision; and
- (iv) The pharmacist submitting a collaborative practice agreement or revisions to an approved collaborative practice agreement to the Board shall not practice under the collaborative practice agreement until notified of approval by the Executive Director.
(f) A pharmacist and prescribing practitioner entering into a collaborative practice agreement must be currently licensed by their respective boards and authorized to practice in this State.
(g) Nothing in this section shall be interpreted to permit a pharmacist to accept delegation of a physician's authority outside the limits included in W.S. § 33-26-402 of the Medical Practice Act and the Wyoming State Board of Medicine regulations.
059-20 Wyo. Code R. § 20-5
Adopted, Eff. 12/19/2018.